JP2006508071A - ホルモン置換療法のための１７β‐エストラジオール／レボノルゲストレル経皮的パッチ - Google Patents
ホルモン置換療法のための１７β‐エストラジオール／レボノルゲストレル経皮的パッチ Download PDFInfo
- Publication number
- JP2006508071A JP2006508071A JP2004541774A JP2004541774A JP2006508071A JP 2006508071 A JP2006508071 A JP 2006508071A JP 2004541774 A JP2004541774 A JP 2004541774A JP 2004541774 A JP2004541774 A JP 2004541774A JP 2006508071 A JP2006508071 A JP 2006508071A
- Authority
- JP
- Japan
- Prior art keywords
- day
- estradiol
- range
- levonorgestrel
- feed rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004400 levonorgestrel Drugs 0.000 title claims abstract description 78
- 238000002657 hormone replacement therapy Methods 0.000 title claims abstract description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims description 149
- 229960005309 estradiol Drugs 0.000 title claims description 48
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 230000037317 transdermal delivery Effects 0.000 claims description 7
- 239000007933 dermal patch Substances 0.000 claims 2
- 239000000583 progesterone congener Substances 0.000 abstract description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract description 3
- DWMXQLDCXDJLRZ-GOAIQXNMSA-N OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DWMXQLDCXDJLRZ-GOAIQXNMSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 35
- 206010016825 Flushing Diseases 0.000 description 18
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000003442 weekly effect Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002357 endometrial effect Effects 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 206010046788 Uterine haemorrhage Diseases 0.000 description 6
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 230000001457 vasomotor Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 206010013990 dysuria Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000006828 endometrial hyperplasia Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 206010029446 nocturia Diseases 0.000 description 4
- 238000009595 pap smear Methods 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 206010006298 Breast pain Diseases 0.000 description 3
- 206010016334 Feeling hot Diseases 0.000 description 3
- 208000006662 Mastodynia Diseases 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 206010003055 Application site reaction Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- RQFMPXMLRRPOJH-ORADRBJOSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RQFMPXMLRRPOJH-ORADRBJOSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107243 climara pro Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000011099 endometrial disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940088468 estradiol / levonorgestrel transdermal system Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/259,892 US20040062794A1 (en) | 2002-09-30 | 2002-09-30 | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
| PCT/US2003/030493 WO2004030675A1 (en) | 2002-09-30 | 2003-09-29 | 17β-ESTRADIOL/LEVONORGESTREL TRANSDERM PATCH FOR HORMONE REPLACEMENT THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508071A true JP2006508071A (ja) | 2006-03-09 |
| JP2006508071A5 JP2006508071A5 (OSRAM) | 2006-11-16 |
Family
ID=32029580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004541774A Pending JP2006508071A (ja) | 2002-09-30 | 2003-09-29 | ホルモン置換療法のための１７β‐エストラジオール／レボノルゲストレル経皮的パッチ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040062794A1 (OSRAM) |
| EP (1) | EP1545547A1 (OSRAM) |
| JP (1) | JP2006508071A (OSRAM) |
| CN (1) | CN1684690A (OSRAM) |
| AU (1) | AU2003279000A1 (OSRAM) |
| BR (1) | BR0314959A (OSRAM) |
| CA (1) | CA2495055A1 (OSRAM) |
| IL (1) | IL166678A0 (OSRAM) |
| MX (1) | MXPA05003364A (OSRAM) |
| RU (1) | RU2005113686A (OSRAM) |
| WO (1) | WO2004030675A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7889336B2 (en) * | 2008-02-01 | 2011-02-15 | Vladimir Yankov | Optical integrated nanospectrometer |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| AU2017394679A1 (en) * | 2016-12-05 | 2019-06-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04504109A (ja) * | 1988-12-16 | 1992-07-23 | ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー | エストロゲン／プロゲスチン経皮投与ユニット，そのシステムとプロセス |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
| US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
| US5560922A (en) * | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
| US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
| US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
| KR960704578A (ko) * | 1993-09-29 | 1996-10-09 | 에드워드 엘. 만델 | 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer) |
| GR1002079B (en) * | 1994-07-26 | 1995-12-05 | Lavipharm A E | System of a special structure and composition for the rapid transdermal administration of oestrogens. |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| US6551611B2 (en) * | 1995-09-28 | 2003-04-22 | Schering Aktiengesellschaft | Hormone replacement therapy method |
| DE19548332A1 (de) * | 1995-12-22 | 1997-07-10 | Rotta Res Bv | Hormonpflaster |
| US5702720A (en) * | 1995-12-22 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
| IT1283102B1 (it) * | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
| US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| US6132760A (en) * | 1997-02-28 | 2000-10-17 | 3M Innovative Properties Company | Transdermal device for the delivery of testosterone |
| US6193996B1 (en) * | 1998-04-02 | 2001-02-27 | 3M Innovative Properties Company | Device for the transdermal delivery of diclofenac |
| US6312715B1 (en) * | 1998-05-01 | 2001-11-06 | 3M Innovative Properties Company | Adhesive microsphere drug delivery composition |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| AU4972599A (en) * | 1998-07-07 | 2000-01-24 | Transdermal Technologies, Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
-
2002
- 2002-09-30 US US10/259,892 patent/US20040062794A1/en not_active Abandoned
-
2003
- 2003-09-29 MX MXPA05003364A patent/MXPA05003364A/es not_active Application Discontinuation
- 2003-09-29 AU AU2003279000A patent/AU2003279000A1/en not_active Abandoned
- 2003-09-29 CN CNA038233819A patent/CN1684690A/zh active Pending
- 2003-09-29 BR BR0314959-5A patent/BR0314959A/pt not_active IP Right Cessation
- 2003-09-29 WO PCT/US2003/030493 patent/WO2004030675A1/en not_active Ceased
- 2003-09-29 JP JP2004541774A patent/JP2006508071A/ja active Pending
- 2003-09-29 CA CA002495055A patent/CA2495055A1/en not_active Abandoned
- 2003-09-29 RU RU2005113686/14A patent/RU2005113686A/ru not_active Application Discontinuation
- 2003-09-29 EP EP03770511A patent/EP1545547A1/en not_active Withdrawn
-
2005
- 2005-02-03 IL IL16667805A patent/IL166678A0/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04504109A (ja) * | 1988-12-16 | 1992-07-23 | ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー | エストロゲン／プロゲスチン経皮投与ユニット，そのシステムとプロセス |
Non-Patent Citations (4)
| Title |
|---|
| JPN5005008066, ＣＨＥＮ Ｇ−Ｓ ｅｔ ａｌ．, ＪＯＵＲＮＡＬ ＯＦ ＣＯＮＴＲＯＬＬＥＤ ＲＥＬＥＡＳＥ, 19950501, Ｖｏｌ．３４， Ｎｏ．２, ｐｐ．１２９−１４３, ＥＬＳＥＶＩＥＲ ＳＣＩＥＮＣＥ ＰＵＢＬＩＳＨＥＲＳ Ｂ． Ｖ． * |
| JPN5005008067, ＶＯＮ ＨＯＬＳＴ ＴＨＯＭＡＳ ｅｔ ａｌ．, ＭＡＴＵＲＩＴＡＳ, 20020325, Ｖｏｌ．４１， Ｎｏ．３, ｐｐ．２３１−２４２, ＥＬＳＥＶＩＥＲ * |
| JPN5005008068, ＰＡＯＬＥＴＴＩ ＡＮＮＡ ＭＡＲＩＡ ｅｔ ａｌ．, ＭＡＴＵＲＩＴＡＳ, 20020625, Ｖｏｌ．４２， Ｎｏ．２, ｐｐ．１３７−１４７, ＥＬＳＥＶＩＥＲ * |
| JPN5005008069, ＧＯＤＳＬＡＮＤ ＩＡＮ, ＦＥＲＴＩＬＩＴＹ ＡＮＤ ＳＴＥＲＩＬＩＴＹ, 200105, Ｖｏｌ．７５， Ｎｏ．５, ｐｐ．８９８−９１５ * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005113686A (ru) | 2006-01-20 |
| IL166678A0 (en) | 2006-01-15 |
| BR0314959A (pt) | 2005-08-02 |
| CA2495055A1 (en) | 2004-04-15 |
| WO2004030675A1 (en) | 2004-04-15 |
| AU2003279000A1 (en) | 2004-04-23 |
| US20040062794A1 (en) | 2004-04-01 |
| EP1545547A1 (en) | 2005-06-29 |
| CN1684690A (zh) | 2005-10-19 |
| MXPA05003364A (es) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10258630B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US11246875B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US11266661B2 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US20070238713A1 (en) | Methods for prevention and treatment of conditions arising from local estrogen deficiency | |
| US20190343771A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US20190022107A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| Marsh et al. | Management of the menopause | |
| US20210213015A1 (en) | Lopinavir and ritonavir for the treatment of cervix disorders | |
| Cicinelli et al. | Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study | |
| US20220047609A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| JP2006508071A (ja) | ホルモン置換療法のための１７β‐エストラジオール／レボノルゲストレル経皮的パッチ | |
| JP2021119155A (ja) | 膣挿入エストラジオール医薬組成物および方法 | |
| Wildemeersch et al. | Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination? | |
| Whitehead | 10 Treatments for menopausal and post-menopausal problems: present and future | |
| French et al. | Mirena®-the levonorgestrel intrauterine system (20 µg/day) | |
| US20250387339A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| US20250387408A1 (en) | Vaginal inserted estradiol pharmaceutical compositions and methods | |
| Prior et al. | Hormonal therapy of gender dysphoria: The female-to-male transsexual | |
| Taemamu et al. | Comparison of estradiol hemihydrate 10 µg vaginal tablets versus vaginal gel in postmenopausal women with vaginal atrophy: A randomized crossover study | |
| Krishna et al. | Hormone Replacement Therapy in Menopausal Women | |
| Pariyanont et al. | Effectiveness and Adverse Drug Reactions of Hormonal Replacement Therapy in Menopausal Women, Health Promotion Center, Region 4 Ratchaburi | |
| Dose | The American College of Obstetricians and Gynecologists recommends the following estro-gen dosages for osteoporosis (l) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100914 |